Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial by Harandi, A. A. et al.
SAGE-Hindawi Access to Research
Stroke Research and Treatment
Volume 2011, Article ID 721613, 5 pages
doi:10.4061/2011/721613
Research Article
Safety and Efﬁcacy of MLC601 in Iranian Patients after Stroke:
ADouble-Blind,Placebo-ControlledClinicalTrial
A.A. Harandi,1,2 R.Abolfazli,3 A.Hatemian,4 K. Ghragozlee,1 M.Ghaffar-Pour,3
M. Karimi,5 S.Shahbegi,5 H.Pakdaman,1 M.Tabasi,6 A.L.Tabatabae,3 andA. Nourian7
1Shaheed Beheshti University of Medical Sciences and Health Services, Tehran 19839-63113, Iran
2Department of Neurology, Loghman Hospital, Shahid Beheshti University of Medical Sciences, Tehran 13336-31151, Iran
3Tehran University of Medical Sciences and Health Services, Tehran, Iran
4Gylan University of Medical Sciences and Health Services, Gylan, Iran
5Milad Hospital, Tehran, Iran
6Social Security, Tehran, Iran
7Azad University of Medical Sciences, Tehran 19168, Iran
Correspondence should be addressed to A. A. Harandi, amini alli@yahoo.com
Received 7 October 2010; Revised 22 February 2011; Accepted 26 April 2011
Academic Editor: Daniel Bereczki
Copyright © 2011 A. A. Harandi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To investigate the safety and eﬃcacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after
ischemic stroke. Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than
3month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day,
as an add-on to standard stroke treatment for 3months. Results. Sex, age, elapsed time from stroke onset, and risk factors in the
treatment group were not signiﬁcantly diﬀe r e n tf r o mp l a c e b og r o u pa tb a s e l i n e( P>. 05). Repeated measures analysis showed that
Fugl-Meyer assessment was signiﬁcantly higher in the treatment group during 12 weeks after stroke (P<. 001). Good tolerability
to treatment was shown, and adverse events were mild and transient. Conclusion. MLC601 showed better motor recovery than
placebo and was safe on top of standard ischemic stroke medications especially in the severe and moderate cases.
1.Introduction
Stroke is one of the major leading causes of death and
disability worldwide [1]. Thrombolytic therapies in selected
patients and antiplatelet prescription have been remained as
just two main approved medications in this setting. Standard
treatment modalities in stroke rehabilitation are limited to
physiotherapy, occupational therapy, and speech therapy
in addition to skilled medical and nursing care. Despite
intensive inpatient rehabilitation with these modalities in
stroke units, about 1/3 of acute stroke patients remained
moderately to severely disabled at discharge time. Many
studies tried to ﬁnd new therapeutic strategies to improve
outcome of treatment in stroke; however, results of several
clinical trials on variety of neuroprotective drugs have been
failed to show eﬃcacy in humans [2].
Some promising combination therapies have been intro-
duced by traditional Chinese medicine (TCM). It consists
of several types of medicinal herbs, based on more than
2500years of clinical experience. MLC601 (NeuroAid) is
a TCM which is used extensively in China to improve
recovery after stroke [3]. It combines several herbal and
animal components. Some studies evaluated its safety and
eﬃcacy. In addition, the neuroprotective and/or neurogen-
erative properties in vitro and in vivo assays have been
assessed. However, further studies are needed to approve the
diﬀerent aspects of eﬀectiveness on mental and poststroke
motor function and also to clear its pharmacokinetics. For
prescription of MLC601 as a standard drug in stroke, more
documents especially in human ﬁeld should be provided to
improvedecisionmakingbasedonevidence-basedmedicine.
For this reason, we decided to investigate the safety and2 Stroke Research and Treatment
eﬃcacy of MLC601 on motor recovery in ischemic stroke
patients.
2. Methods
2.1. Study Design and Subjects. In a double-blind, placebo-
controlled clinical study, the safety and eﬃcacy of Neu-
roAid (Moleac Pte. Ltd, Singapore) were compared with
controlsinischemicstroke.Thestudyprotocolwasregistered
in http://ClinicalTrials.gov/(Identiﬁer: NCT01336153). The
period of the recruitment was from July 2009 to February
2010. The subjects were recruited from in- and out-clinic
patients from Iran. Blocked randomization was used to
randomly allocate 100 and 50 participants to MLC601 and
placebo group, respectively. Block sizes of 2 and 3 and an
allocation ratio of 2:1 (e.g., ABABAA and ABABAAABA)
were applied in witch A was twofold more than B. The study
proﬁle is supplied as Figure 1.
Both drug and placebo were similarly packaged and
m a r k e da sAo rB ,r e s p e c t i v e l y .A l ls u b j e c t sw e r ea l l o c a t e dt o
either group A (100 patients; NeuroAid 400mg, 4 capsules
3 times daily) or group B (50 patients; placebo, 4 capsules
3 times daily) and received placebo or NeuroAid for 3
months. MLC601 (0.4g per capsule) combines 9 herbal
(0.57g Radix astragali, 0.114g Radix salvia miltiorrhizae,
0.114g Radix paeoniae rubra, 0.114g Rhizoma chuanxiong,
0.114g Radix angelicae sinensis, 0.114g Prunus persica,
0.114g Carthamus tinctorius, 0.114g Radix polygalae,a n d
0.114gRhizomaacoritatarinowii,)and5animalcomponents
(0.0285g Cornu saigae tataricae, 0.095g Buthus martensii,
0.0665 Hirudo, 0.0665g Eupolyphaga seu steleophaga,a n d
0.0285g Calculus bovis artifactus). In order to prepare the
placebo, similar capsules in shape and color were ﬁlled
with ﬂour as inert chemical structure, thus making them
indistinguishable from the original capsules. The patients
were visited at the beginning and every 10 days in the ﬁrst
month and every two weeks in the second and third months.
NeuroAid or placebo was added to the standard regimen
of patients including antiplatelet, anticoagulant, liplowering,
antihypertensive, and antidiabetic, medications. Treatment
was initiated between 1 week and 3 months after stroke. All
patients underwent neurological evaluation, computerized
tomography (CT), magnetic resonance imaging (MRI) of
brain, electrocardiogram, blood investigation, full blood
count, renal function test, liver function test, electrolytes,
prothrombin time (PT), and partial thromboplastin time
( P T T )a tﬁ r s ta n dm o n t h l y .
Inclusion criteria were age between 30–72 years, less than
one month after stroke, ischemic cerebral stroke, and signed
informed consent form. Exclusion criteria were treatment
with thrombolytic, ischemic stroke combined with hemor-
rhage, severe renal or liver failure, dementia, psychosis and
history of seizure disorder, history of previous stroke, and
hemoglobin level less than 10mg/dL on admission.
2.2. Outcome Measure. The eﬃcacy endpoint was improve-
ment in aﬀected upper and lower limbs impairment as
assessed by the Fugl-Meyer assessment (FMA) scale at
baseline, 4, 8, and 12 weeks. Patients were categorized into 3
208 patients were
screened
NeuroAid group
(A) 100 patients
100 patients
successfully
ﬁnished the study
50 patients
successfully
ﬁnished the study
Placebo group (B)
50 patients
Randomization
150 patients fulﬁlled
the criteria
Figure 1: The study proﬁle.
categories according to their baseline FMA score at initiation
of the clinical trial: severe (0–55), moderate (56–80), and
mild (81–100).
The data were analyzed with independent t-test and
repeated measured analysis using SPSS version 11.0 software
(SPSSInc.,Chicago,Ill,USA).P values ≤.05wereconsidered
statistically signiﬁcant.
2.3. Ethical Issues. The study was conducted in accordance
with the principles embodied in the declaration of Helsinki,
and the project design was approved by an appropriate
institutional ethics committee. All patients or in cases with
severe disability their ﬁrst relatives had signed an informed
consent form.
3. Results
Patients were neither excluded nor withdrawn or lost to
followup. The NeuroAid and the control group had similar
baseline characteristics in gender, age, elapsed time from
stroke onset, and stroke severity (Table 1). Table 2 shows
the FMA scores comparison between the NeuroAid and the
p l a c e b og r o u p sa tf o u rd i ﬀerent points in time, that is, at
baseline, 4, 8, and 12weeks after stroke. By generalized linear
model, repeated measured analysis was performed which
showed a statistically signiﬁcant diﬀerence in trend of FMA
in two groups during 12 months of followup (P<. 0001;
Figure 2).
Satety. There were no severe side eﬀects which led to discon-
tinuation of NeuroAid. The common side eﬀects were mild
and transient nausea and vomiting in 7 patients who took
NeuroAid. There were no abnormal changes in blood count
or renal and liver function.
4. Discussion
Our results cleared that considering FMA, patients who
received MLC601 showed signiﬁcantly better motor recoveryStroke Research and Treatment 3
Table 1: Baseline characteristics of two groups.
Group NeuroAid Placebo P value
(N = 100) (N = 50)
Sex (male) N(%) 48 (48%) 24 (52%) .99
Age (mean ± SD) 64.41 ±5.89 66.14 ±5.36 .08
Risk factors
Hypertension 56 31 .48
Diabetic mellitus 43 22 .90
Hyperlipidemia 48 22 .64
Ischemic heart disease 7 3 .99
Smoking 11 5 .99
Stroke details
Days since stroke 9.45 ±5.39 8.92 ±3.51 .53
Site of the hemiparesis
Right 47 24 .90
Left 53 26
Table 2: Fugl-Meyer Assessment score at baseline and after treatment in the NeuroAid and the placebo group.
FMA NeuroAid (no. = 100) Placebo (no. = 50) P value
Baseline 53.69 ±23.01 54.96 ±24.27 .755
4 weeks after intervention 77.13 ±19.22 63.50 ±24.21 <.001∗
8 weeks after intervention 82.51 ±14.27 72.06 ±21.41 .001∗
12 weeks after intervention 86.22 ±12.34 74.36 ±18.1 <.001∗
FMA: Fugl-Meyer assessment. ∗Statistically signiﬁcant.
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Figure 2: FMA scores in two grups at baseline, 4, 8, and 12 weeks
(repeated measure analysis). P value for groups =.003; P value for
time <.0001; P value for interaction between groups and time for 3
times after intervention =.439.
than placebo group after 4, 8, and 12 weeks. The improve-
ment was mostly manifested after ﬁrst month and developed
more during 12 weeks. In addition, no considerable side
eﬀects were recorded. In this study, we focused on motor
function to obtain more speciﬁc and reliable data. Our
ﬁndings provide a new evidence to support eﬃcacy and
tolerability of MLC601 in post ischemic stroke patients.
Clinical researches based on TCM have provided new
treatments for cerebral infarction. More than 100 TCM
agents have been approved by Chinese National Drug
Administration and are used clinically in China for stroke
[4]. It was developed to aid poststoke recovery and was
approved in 12 countries including Iran. Pharmacological
studies demonstrated some TCMs to have antioxidant, anti-
inﬂammatory, and antiglutamate eﬀects [5]. However, these
have limited acceptability by Western medicine because of
lack of available evidences for the eﬃcacy and safety of
TCM [3]. A recent meta-analysis of TCM for ischemic stroke
only found clinical trial reports for 59 TCM and concluded
that the methodological quality of most trials were poor.
According to this report, only 3 studies were randomized,
double-blind, and placebo-controlled, in which 2 had long-
term outcome assessments [4]. It is clear that further large,
well-designed trials are necessary.
Early trials of MLC601 were performed in China on 605
patients in 2000, established its safety, and demonstrated a
positive eﬀect on the recovery of independence and motor
functions. The patients were found to be 2.4 times more
likely to achieve independence at 1 month after stroke than
the control group [3, 6, 7]. Our results showed the same
tendency for better recovery in the ﬁrst month.
Two similar randomized clinical trials comparing the
eﬃcacy and safety of NeuroAid and BNJ (a TCM approved
by the Sino Food and Drug Administration) in subjects with
recent ischemic stroke were included in a pooled analysis.4 Stroke Research and Treatment
Twohundredsubjectswererandomizedintheﬁrststudyand
405 in the second. Most of separate motor function pooled
analyses showed an advantage in those subjects randomized
to the MLC601 treatment group compared with the control
group. Speciﬁcally, MLC601 decreased the scores at 1 month
for the 2 domains of upper limb and distal lower limbs
as compared with the active control. A numeric decrease
in the scores for lower limb and facial and distal upper
limb functions was shown without statistically signiﬁcant
diﬀerences. No signiﬁcant eﬀect was observed on visual and
language functions. Drug was well tolerated in two trials
[3].
In a double-blind, placebo-controlled pilot study by
Kong et al. that was more similar to our study, the eﬃcacy
of NeuroAid on motor recovery in ischemic stroke patients
was assessed using rehabilitation endpoints. Forty subjects
less than one month postischemic stroke were given either
NeuroAid or placebo, 4 capsules 3 times a day for 4
weeks. FMA, National Institute of Health Stroke Scale and
Functional Independence Measure scores were measured
at baseline, 4 and 8 weeks. None of the outcomes were
signiﬁcantly diﬀerent from placebo group except for FMA
scores. Consistent with our study, FMA scores showed a
positive trend for improvement with NeuroAid treatment
over time. Posterior circulation and severe stroke subjects
showed a tendency for better recovery [8].
In a case series, 10 patients received NeuroAid 4 tablets,
3 times per day between 1 week and 6 months after stroke
for 2-3months. The patients showed a good tolerability
and only 1 patient reported diarrhea as a mild side eﬀect
after starting NeuroAid. During follow-up period, all cases
reported improvements in which 6, 3, and 1 patients showed
full, good or moderate and poor recovery, respectively.
Signiﬁcant improvements were recorded in motor, visual,
speech, and cognitive functions [7].
In a multicentre study called Chinese Medicine MLC601
EﬃcacyonStrokerecovery(CHIMES),atotalof114patients
were recruited after Month 3. At the time of analysis, 13
patients were lost to followup. Therefore, only 51 patients
on treatment A and 49 on treatment B had laboratory data
availableforthisanalysis.Accordingtointerimanalysis,there
were neither statistically or clinically signiﬁcant diﬀerences
between groups in biochemical, heamatological, or ECG
tests nor in the absolute and relative changes in the various
parameters over 3 months. This study is still ongoing [9].
Inarodentmodeloffocalischemia,NeuroAid(MLC601)
and NeuroAid II (MLC901) showed interesting neuropro-
tective and neurogenesis beneﬁts both in vivo and in vitro
at diﬀerent stages after stroke. MLC901 treatment, when
administered in vivo in before or after treatments improved
animal survival as well as functional neurological recovery
and decreased neurodegeneration without aﬀecting physi-
ological parameters. MLC601 and MLC901 also prevented
neuronal death in vivo and in vitro model of excitotoxicity
and could induce neurogenesis in rodent and human cells,
promote cell proliferation as well as neurite outgrowth and
stimulate the development of a dense axonal and dendritic
network [10]. We believe it was one of the most interesting
studies with most precise results in this ﬁeld.
Furthermore, it has been recently shown that NeuroAid,
taken either alone or in combination with aspirin, does not
change hemostasis, hematology, and biochemistry in normal
subjects and stroke patients [11]. Therefore, it can be used
safely with the mentioned drug. It was also well tolerated in
our study.
5. Conclusion
Our study as a randomized, double-blind, placebo-
controlled clinical trial shows signiﬁcant motor recovery
and NeuroAid was safe on top of standard ischemic stroke
medication. However, still more clinical trials are needed to
evaluate safety and eﬃcacy of NeuroAid for stroke recovery
before such treatments can be recommended for routine
and standard poststroke treatment. Many questions still
remained to be answered, for example, what are interactions
with other drugs, when is the optimal time for initiation of
therapy, how long is duration of treatment,whichagegroups
are the best candidate, and what are the long term-beneﬁts.
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